Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$NBIX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.43 up 31.19% YoY • Reported revenue of $959M up 39.49% YoY • Neurocrine Biosciences raised full year 2026 INGREZZA net product sales guidance to a range of $2.825 billion to $2.875 billion, up from the prior range of $2.7 billion to $2.8 billion.

Price since post

Full Details

Advertisement|Remove ads.